Gt biopharma's next generation camelid trike® nanobody platform highlighted at esmo congress 2021

Beverly hills, calif., sept. 20, 2021 /prnewswire/ -- gt biopharma, inc. (the "company") (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike platform, today announced dr. jeffrey miller's mini-oral presentation at the european society for medical oncology (esmo) congress 2021.
GTBP Ratings Summary
GTBP Quant Ranking